Aptorum gains on blood-based pathogen surveillance tech licensed from A*STAR

In a sign of growing enthusiasm for liquid biopsy technologies and the urgent need for pathogen surveillance systems, Aptorum Group nearly tripled its share price after launching a subsidiary for blood-based diagnostics for infectious diseases.

Aptorum Group Ltd. (NASDAQ:APM) closed up $3.54 (290%) to $4.76 on Tuesday after launching Aptorum Innovations with technology licensed from Singapore’s Agency for Science, Technology and Research (A*STAR). The licensing deal was established with Accelerate Technologies Pte. Ltd., the commercialization arm of A*STAR; financial details were not disclosed...